IL-8
IL-8/CXCL8 is a CXC chemokine produced during inflammation that activates neutrophils, inducing chemotaxis, exocytosis, respiratory burst, and neutrophil accumulation in vivo[1]. Mechanistically, IL-8 acts through CXCR1/CXCR2 to control target-cell adhesion, migration, and function, while downstream signaling supports actin remodeling, calcium mobilization, granule exocytosis, and respiratory burst[2]. In inflammatory and cancer contexts, the CXCL8-CXCR1/2 axis participates in inflammatory mediator trafficking, tumor progression, metastasis, and diseases including COPD, asthma, cystic fibrosis, and cancer[3]. Compared with related ELR+ CXC chemokines, IL-8 is distinguished by dual activation of CXCR1 and CXCR2, whereas CXCR2 also recognizes CXCL1, CXCL2, CXCL3, CXCL5, CXCL6, and CXCL7[4]. CXCL8 monomers and dimers differentially regulate CXCR1 and CXCR2, supporting receptor-selective experimental designs for neutrophil recruitment and cytotoxic activity studies[4]. For experimental applications, noncompetitive allosteric CXCR1/CXCR2 inhibitors block inflammatory CXCL8 receptor signaling, and CXCL8-derived antagonists can reduce neutrophil infiltration in inflammatory models[5][6].
References:
- [1]. Baggiolini M, et al. Interleukin-8, a chemotactic and inflammatory cytokine. FEBS Lett. 1992 Jul 27;307(1):97-101. [Content Brief]
- [2]. Matsushima K, et al. Interleukin-8: An evolving chemokine. Cytokine. 2022 May;153:155828. [Content Brief]
- [3]. Ha H, et al. Role of the CXCL8-CXCR1/2 Axis in Cancer and Inflammatory Diseases. Theranostics. 2017 Apr 7;7(6):1543-1588. [Content Brief]
- [4]. Nasser MW, et al. Differential activation and regulation of CXCR1 and CXCR2 by CXCL8 monomer and dimer. J Immunol. 2009 Sep 1;183(5):3425-32. [Content Brief]
- [5]. Bertini R, et al. Noncompetitive allosteric inhibitors of the inflammatory chemokine receptors CXCR1 and CXCR2: prevention of reperfusion injury. Proc Natl Acad Sci U S A. 2004 Aug 10;101(32):11791-6. [Content Brief]
- [6]. Gordon JR, et al. The combined CXCR1/CXCR2 antagonist CXCL8(3-74)K11R/G31P blocks neutrophil infiltration, pyrexia, and pulmonary vascular pathology in endotoxemic animals. J Leukoc Biol. 2005 Dec;78(6):1265-72. [Content Brief]
-
IL-8 Related Products (103)
Related Products (103)
-
Recombinant Proteins (16)
-
Nadifloxacin (Standard)
0 ImagesSynonyms: OPC7251 (Standard)Nadifloxacin (Standard) is the analytical standard of Nadifloxacin (HY-B0506). This product is intended for research and analytical applications. Nadifloxacin (OPC7251) is a broad-spectrum quinolone antibiotic. Nadifloxacin inhibits bacterial DNA gyrase and topoisomerase IV, interfering with DNA replication. It also suppresses the production of proinflammatory cytokines (such as IL-1α, IL-6, and IL-8). Nadifloxacin exhibits antibacterial activity against various pathogens, including Propionibacterium acnes and Staphylococcus aureus. Nadifloxacin also exhibits anti-inflammatory activity. Nadifloxacin can be used in the research of skin infections such as acne vulgaris, folliculitis, and impetigo.
-
Nadifloxacin-d5
0 ImagesCat. No.: HY-B0506S1Synonyms: OPC7251-d5Nadifloxacin-d5 (OPC7251-d5) is deuterium labeled Nadifloxacin (HY-B0506). Nadifloxacin (OPC7251) is a broad-spectrum quinolone antibiotic. Nadifloxacin inhibits bacterial DNA gyrase and topoisomerase IV, interfering with DNA replication. It also suppresses the production of proinflammatory cytokines (such as IL-1α, IL-6, and IL-8). Nadifloxacin exhibits antibacterial activity against various pathogens, including Propionibacterium acnes and Staphylococcus aureus. Nadifloxacin also exhibits anti-inflammatory activity. Nadifloxacin can be used in the research of skin infections such as acne vulgaris, folliculitis, and impetigo.
